Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Kenvue $7.75 billion senior notes offering
The investment-grade offering comprises eight tranches of notes
Atairos acquisition of LifeLabs Learning
We are advising Atairos on the transaction
Cigna $1.5 billion senior notes offering
The senior notes are due 2026 and 2033
Revolution Medicines $345 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Ardelyx $150 million at-the-market offering
The shares are listed on the Nasdaq Global Market
European Biotech Acquisition $220 million combination with Oculis
We advised European Biotech Acquisition on its de-SPAC transaction
Eli Lilly $4 billion notes offering
The investment-grade notes are due 2026, 2033, 2053 and 2063
CStone Pharmaceuticals HK$392.9 million placing of new shares
We advised CStone Pharmaceuticals on the placement
CureVac $250 million follow-on offering
We advised CureVac on the equity offering
RxSight $50 million follow-on offering
The stock is listed on the Nasdaq Global Market